Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine

Therapy of depression is a current problem in psychiatry. Agomelatine is not inferior to other modern drugs in terms of antidepressant efficacy (response and remission rates) and is characterized by the best tolerability.Objective: to evaluate the efficacy and safety of agomelatine in the treatment of nonpsychotic depression with a single and recurrent course.Material and methods. Patients (n=37) with a current depressive episode (DE; F32 according to ICD-10), mean age 41.2±2.07 years, were studied. Clinical psychopathological and psychometric methods were used in the study (Hamilton Hospital Depression Scale – HAMD-17; Spielberger–Khanin Anxiety Self-Assessment Scale, Sheehan Anxiety Scale, Clinical Global Impression Scale – CGI-I). A single DE was diagnosed in 62.2% of patients, and recurrent depressive disorder in 37.8%. Stress-related onset of current DE was found in 56.8% of cases, autochthonous in 43.2%.Results. 94.6% of patients were responders, including 68.6% who went into remission. A statistically significant decrease in scores on the HAMD-17 scale was noted in the remission group from the 7th day of agomelatine therapy (p<0.05), in the responder group – from the 14th day of therapy (p<0.05). According to the Sheehan scale, a statistically significant decrease in scores was noted at the end of the first week of therapy (p<0.05), according to the Spielberger–Khanin scale – in the second week (p<0.05) in all patients. According to the CGI-I scale, the condition at the end of therapy improved in 57.1% of patients, significantly in 42.9%. Clinical predictors of therapeutic response in patients with remission included significantly higher frequency of a single DE (p<0.02), moderate severity of current depression (p<0.02), dizziness among autonomic disorders (p<0.01), a significantly lower representation of the melancholic type of depression (p<0.05), a symptom of a gloomy and pessimistic vision of the future (p<0.05), sleep disturbances (p<0.04), a factor of personal significance in the form of a threat in patients with stress-provoked onset of the current DE (p<0.05).Adverse events occurred in the first week of treatment with agomelatine in 14.3% of cases (nausea – 8.6%, headache and dizziness – 2.9% each), they were mild and did not require discontinuation of the drug. Two patients taking agomelatine at a dose of 50 mg discontinued the study: in one case persisted social phobia, increased fatigue, motor retardation, and persistent modern insomnia; in the other case – a pronounced senestoalgic syndrome with cerebral localization.Conclusion. Agomelatine therapy has been shown to be highly effective and well tolerated in nonpsychotic depression.

show abstract

Experience with agomelatine therapy for non-psychotic depression with a single and recurrent course

Ivanova

Kovaleva

Sitnikova

2023

RJTAO

View full text Add to dashboard Cite

show abstract

Depression as an independent risk factor for cardiovascular diseases and cognitive impairment in people aged 25-44 years

Gafarov,

Sukhanov,

Gromova

et al. 2024

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To establish associations between the depression level as an independent cardiovascular risk factor and cognitive impairment (patterns of memory, attention and thinking) in people aged 25-44 years.Material and methods. In 2013-2016, a random representative sample of people aged 25-44 years was studied in one of the Novosibirsk districts. A total of 463 men (mean age 35,94±5,96 years) and 546 women (mean age 36,17±5,99 years) were examined. Standardized tests were used to assess cognitive function. Depression level was assessed according to the MOPSY (MONICA-psychosocial) World Health Organization program criteria.Results. In the surveyed random representative sample of people aged 25-44 years, the prevalence of higher education was the highest (60,5%). The depression prevalence in women was higher than in men: high depression level — 15,84 and 8,64%; the mean depression level was 25,71 and 21,3%, respectively. Univariate analysis showed that the attention stability according to the dot cancellation test at a moderate and high depression level was reduced only in men with higher education, compared with those without depression (p=0,018). In persons of both sexes with secondary professional education in a random representative sample of persons aged 25-44 years, associations between depression and memory pattern disturbances were identified. In the resulting multivariate model, men in a random representative sample of persons aged 25-44 years without depression did not have any cognitive impairment in patterns of memory, attention and thinking.Conclusion. An association has been established between the depression and cognitive impairment (patterns of memory, attention and thinking) in people aged 25-44 years.

show abstract

Complex therapy of psychosomatic disorders associated with the female reproductive cycle

Petelin,

Kondrateva,

Dzhibladze

et al. 2023

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine

Cited by 4 publications

References 9 publications

Experience with agomelatine therapy for non-psychotic depression with a single and recurrent course

Experience with agomelatine therapy for non-psychotic depression with a single and recurrent course

Depression as an independent risk factor for cardiovascular diseases and cognitive impairment in people aged 25-44 years

Complex therapy of psychosomatic disorders associated with the female reproductive cycle

Contact Info

Product

Resources

About